论文部分内容阅读
目的:分析与探讨莫西沙星序贯疗法对于支气管肺炎治疗的疗效与经济学效果。方法:选取支气管肺炎患者共57例随机分为2组。观察组(29例)在常规治疗的基础上采用莫西沙星序贯疗法治疗,对照组(28例)在常规治疗的基础上采用莫西沙星400 mg,ivd qd。对比两组患者的临床疗效、症状改善、住院时间、不良反应和成本等指标。结果:观察组临床总有效率为96.55%,对照组为92.86%,两组差异无统计学意义(P>0.05)。观察组的体温正常时间、胸片检查正常时间、咳嗽停止时间较对照组时间短(P<0.05),两组住院时间及不良反应发生率比较,差异无统计学意义(P>0.05)。莫西沙星序贯疗法治疗支气管肺炎成本低于常规疗法。结论:采用莫西沙星序贯疗法治疗支气管肺炎与常规治疗效果相当,但治疗成本较低。
Objective: To analyze and explore the efficacy and economic effect of sequential therapy of moxifloxacin in the treatment of bronchial pneumonia. Methods: A total of 57 patients with bronchial pneumonia were randomly divided into two groups. The observation group (n = 29) was treated with moxifloxacin sequential therapy on the basis of routine treatment. The control group (n = 28) received moxifloxacin 400 mg, ivd qd on the basis of routine treatment. The clinical efficacy, symptoms, hospital stay, adverse reactions and cost were compared between the two groups. Results: The total clinical effective rate was 96.55% in the observation group and 92.86% in the control group. There was no significant difference between the two groups (P> 0.05). The observation group’s normal body temperature, chest X-ray examination normal time, cough stop time shorter than the control group (P <0.05), two groups of hospital stay and the incidence of adverse reactions, the difference was not statistically significant (P> 0.05). Moxifloxacin sequential therapy for bronchial pneumonia cost less than conventional therapy. Conclusion: The sequential therapy of moxifloxacin is equivalent to conventional treatment for bronchopneumonia, but the treatment cost is lower.